XML 52 R42.htm IDEA: XBRL DOCUMENT v3.19.1
Acquisitions and Divestiture (Narrative) (Details)
$ in Millions
1 Months Ended 3 Months Ended
Feb. 15, 2019
USD ($)
Apr. 30, 2019
USD ($)
medicine
Jun. 30, 2019
USD ($)
Mar. 31, 2019
USD ($)
Mar. 31, 2018
USD ($)
Business Acquisition [Line Items]          
Acquired in-process research and development (Note 3)       $ 136.9 $ 0.0
Loxo Oncology, Inc.          
Business Acquisition [Line Items]          
Purchase price $ 6,920.0        
Discovery, development, and commercialization of potential new medicines | Avidity Biosciences, LLC | Scenario, Forecast          
Business Acquisition [Line Items]          
Acquired in-process research and development (Note 3)     $ 25.0    
Discovery, development, and commercialization of potential new medicines | Subsequent Event | Avidity Biosciences, LLC          
Business Acquisition [Line Items]          
License and research collaboration agreement, upfront fee   $ 20.0      
License and research collaboration agreement, investment, amount   $ 15.0      
Legacy Antibiotic Medicines and Manufacturing Facility in Suzhou, China | Disposal Group, Held-for-sale, Not Discontinued Operations | Subsequent Event | Eddingpharm          
Business Acquisition [Line Items]          
Number of medicines, rights to, agreed to be sold | medicine   2      
Disposal group, not discontinued operation, deposit to be received   $ 75.0      
Disposal group, not discontinued operation, payment to be received   $ 300.0